Quinnova Pharmaceuticals Launches Salvax (Hydrating Topical Foam) for treatment of hyperkeratotic conditions such as psoriasis

[Guest guest]

Quinnova Pharmaceuticals, Inc. Launches Salvax (Hydrating Topical Foam)

www.therapeuticsdaily.com/news/article.cfm?contentvalue=595564 & contenttype=newsa\

rchive & channelID=29

From the PharmaLive.com News Archive - Jan. 05, 2009

NEWTOWN, Pa.--Jan 5, 2009 - Quinnova Pharmaceuticals, Inc. announced today

the launch of Salvax (Hydrating Topical Foam) Rx for the treatment of

hyperkeratotic conditions such as psoriasis, keratosis pilaris, and xerosis.

Salvax (Hydrating Topical Foam) contains 6% salicylic acid, a potent

keratolytic agent, formulated in a water-lipid based foam. The product

utilizes Quinnova's patented Proderm TechnologyTM, containing a unique

combination of physiological lipids, dimethicone, and glycerin which

together help to restore the skin barrier, hydrate, and protect the skin, in

addition to having anti-inflammatory properties.

" Salvax (Hydrating Topical Foam) is a great addition to our current

portfolio of products based on Proderm TechnologyTM, " said S. Day,

Quinnova's President & CEO. " When physicians are treating hyperkeratotic

conditions, they can choose their product or active ingredient of choice -

either Salvax (Hydrating Topical Foam) or Hydro 40® Foam. Both products

share the therapeutic and cosmetic benefits of Proderm TechnologyTM while

providing an active ingredient of the physician's preference (urea 40% or

salicylic acid 6%). "

Salvax (Hydrating Topical Foam) differs from other topical salicylic acid 6%

products (creams or lotions). First and foremost, Salvax (Hydrating Topical

Foam) is more than a keratolytic agent which simply removes plaques, scales,

and thickened dry skin. Due to the Proderm TechnologyTM, Salvax (Hydrating

Topical Foam) also addresses the underlying issues of a compromised skin

barrier associated with hyperkeratotic conditions. It repairs and enhances

the skin barrier function by replenishing lost lipids, thus resulting in a

reduced trans-epidermal water loss (TEWL).

The water-lipid nature of the foam allows the foam ingredients to be rapidly

absorbed and incorporated into the outer layers of the skin. Furthermore,

the foam provides a cosmetically elegant feel in addition to ease of

application because it is non-greasy and spreads easily, especially on hairy

regions of the body where the foam does not tangle hair. Unlike some topical

foam preparations, Proderm TechnologyTM does not use either alcohol or other

organic solvents, therefore it is well tolerated by patients.

The product features and benefits of Salvax (Hydrating Topical Foam) provide

added value to treatment efficacy, patient tolerability, and convenience in

use, thereby helping to increase compliance and maximized treatment results.

Quinnova Pharmaceuticals' sales force calls on dermatologists and

podiatrists across the United States.

About Quinnova Pharmaceuticals, Inc.

Quinnova Pharmaceuticals, Inc. is a specialty pharmaceutical company focused

on the development and commercialization of prescription drug products based

on innovative topical drug delivery platforms. For more information, please

visit www.quinnova.com.